Patents by Inventor James Robert Henry

James Robert Henry has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • KRAS INHIBITORS
    Publication number: 20250289830
    Abstract: The present invention provides compounds of the formula: wherein A, B, D1, X, Y, Z, G, R1, R2, and R3a are as described herein, pharmaceutically acceptable salts thereof, and methods of using these compounds and pharmaceutically acceptable salts thereof for treating patients for cancer.
    Type: Application
    Filed: May 29, 2025
    Publication date: September 18, 2025
    Inventors: David Anthony BARDA, Mario BARBERIS, Jolie Anne BASTIAN, Matthew Patrick BAUMGARTNER, Santiago CARBALLARES MARTIN, Kelly Wayne FURNESS, Pablo GARCIA LOSADA, Deqi GUO, Sonia Maria GUTIERREZ SANFELICIANO, James Robert HENRY, Richard Duane JOHNSTON, Jason Eric LAMAR, Tao LIU, Wenceslao LUMERAS AMADOR, Victoriano MOLERO FLÓREZ, Maria Lourdes PRIETO VALLEJO, Michael John RODRIGUEZ, Isabel ROJO, Almudena RUBIO, Chong SI, Gaiying ZHAO, Mohammad Sadegh ZIA-EBRAHIMI
  • KRas inhibitors
    Patent number: 12351591
    Abstract: The present invention provides compounds of the formula: wherein A, B, D1, X, Y, Z, G, R1, R2, and R3a are as described herein, pharmaceutically acceptable salts thereof, and methods of using these compounds and pharmaceutically acceptable salts thereof for treating patients for cancer.
    Type: Grant
    Filed: March 24, 2023
    Date of Patent: July 8, 2025
    Assignee: ELI LILLY AND COMPANY
    Inventors: David Anthony Barda, Jolie Anne Bastian, Kelly Wayne Furness, Deqi Guo, James Robert Henry, Richard Duane Johnston, Jason Eric Lamar, Tao Liu, Michael John Rodriguez, Almudena Rubio, Chong Si, Gaiying Zhao, Mohammad Sadegh Zia-Ebrahimi, Matthew Patrick Baumgartner, Isabel Rojo, Mario Barberis, Santiago Carballares Martin, Pablo Garcia Losada, Sonia Maria Gutierrez Sanfeliciano, Wenceslao Lumeras Amador, Victoriano Molero Florez, Maria Lourdes Prieto Vallejo
  • KRAS INHIBITORS
    Publication number: 20240368193
    Abstract: The present invention provides compounds of the formula: wherein A, Z, G, R1, R2, and R4 are as described herein, pharmaceutically acceptable salts thereof, and methods of using these compounds and pharmaceutically acceptable salts thereof for treating patients for cancer.
    Type: Application
    Filed: March 29, 2024
    Publication date: November 7, 2024
    Inventors: Adedoyin David ABRAHAM, Alberto VALERO DE LA CRUZ, Alicia MARCOS LLORENTE, Alvaro ENRIQUEZ GARCIA, Andrew DILGER, Deqi GUO, Desta BUME, Frederic LAURENT CORDIER, Gaiying ZHAO, Isabel ROJO GARCIA, James Robert HENRY, Jason Eric LAMAR, Jolie Anne BASTIAN, Maria Lourdes PRIETO VALLEJO, Mario BARBERIS, Matthew Patrick BAUMGARTNER, Miguel GARZÓN SANZ, Pablo GARCIA LOSADA, Ramkumar RAJAMANI, Richard Duane JOHNSTON, Robert HAZLITT, Santiago CARBALLARES MARTIN, Sean ARONOW, Shane Michael WALLS, Sonia Maria GUTIERREZ SANFELICIANO, Steven ANDREWS, Timothy Scott KERCHER, Victoriano MOLERO FLÓREZ, Wenceslao LUMERAS AMADOR, William Rush SCAGGS, Juan Antonio RINCON CABEZUDO, Julián PRIEGO SOLER, Xiaohong CHEN
  • SUBSTITUTED FUSED AZINES AS KRAS G12D INHIBITORS
    Publication number: 20240228511
    Abstract: The present invention provides compounds of the formula where R1, R2, R3, R4a, R4b, R4c, R5, R6, X, Y, and Z are as described herein, pharmaceutically acceptable salts thereof, and methods of using these compounds and pharmaceutically acceptable salts thereof for treating patients for cancer.
    Type: Application
    Filed: June 8, 2022
    Publication date: July 11, 2024
    Inventors: David Anthony BARDA, Joshua Ryan CLAYTON, Jeffry Bernard FRANCISKOVICH, Kelly Wayne FURNESS, Douglas Linn GERNERT, James Robert HENRY, Richard Duane JOHNSTON, Spencer Brian JONES, Jason Eric LAMAR, Adam Marc LEVINSON, Curren Tapfuma MBOFANA, Michael John RODRIQUEZ, Almudena RUBIO, Chong SI, Gaiying ZHAO, Mohammed Sadegh ZIA-EBRAHIMI
  • KRAS INHIBITORS
    Publication number: 20240043451
    Abstract: The present invention provides compounds of the formula: wherein A, B, D1, X, Y, Z, G, R1, R2, and R3a are as described herein, pharmaceutically acceptable salts thereof, and methods of using these compounds and pharmaceutically acceptable salts thereof for treating patients for cancer.
    Type: Application
    Filed: March 24, 2023
    Publication date: February 8, 2024
    Inventors: David Anthony BARDA, Jolie Anne BASTIAN, Kelly Wayne FURNESS, Deqi GUO, James Robert HENRY, Richard Duane JOHNSTON, Jason Eric LAMAR, Tao LIU, Michael John RODRIGUEZ, Almudena RUBIO, Chong SI, Gaiying ZHAO, Mohammad Sadegh ZIA-EBRAHIMI, Matthew Patrick BAUMGARTNER, Isabel ROJO, Mario BARBERIS, Santiago CARBALLARES MARTIN, Pablo GARCIA LOSADA, Sonia Maria GUTIERREZ SANFELICIANO, Wenceslao LUMERAS AMADOR, Victoriano MOLERO FLOREZ, Maria Lourdes PRIETO VALLEJO
  • 1-tetrahydropyranylcarbonyl-2,3-dihydro-1H-indole compounds for treating cancer
    Patent number: 10759786
    Abstract: The present invention relates to certain novel 2,3-dihydro-1H-indole compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat cancer, more particularly for the treatment of cancer selected from the group consisting of melanoma, acute myeloid leukemia, chronic lymphocytic leukemia, colorectal cancer, breast cancer, lung cancer, ovarian cancer, fallopian tube carcinoma, primary peritoneal carcinoma, cervical cancer, gastric cancer, liver cancer, pancreatic cancer, thyroid cancer, glioblastoma, non-Hodgkin's lymphoma, and Hodgkin's lymphoma.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: September 1, 2020
    Assignee: Eli Lilly and Company
    Inventors: Jolie Anne Bastian, Jiehao Chen, Jeffrey Daniel Cohen, James Robert Henry, William Thomas McMillen, Bradley Earl Reaman, Almudena Rubio, Daniel Jon Sall, Gaiying Zhao
  • 1-TETRAHYDROPYRANYLCARBONYL-2,3-DIHYDRO-IH-INDOLE COMPOUNDS FOR TREATING CANCER
    Publication number: 20190161477
    Abstract: The present invention relates to certain novel 2,3-dihydro-1H-indole compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat cancer, more particularly for the treatment of cancer selected from the group consisting of melanoma, acute myeloid leukemia, chronic lymphocytic leukemia, colorectal cancer, breast cancer, lung cancer, ovarian cancer, fallopian tube carcinoma, primary peritoneal carcinoma, cervical cancer, gastric cancer, liver cancer, pancreatic cancer, thyroid cancer, glioblastoma, non-Hodgkin's lymphoma, and Hodgkin's lymphoma.
    Type: Application
    Filed: May 31, 2017
    Publication date: May 30, 2019
    Inventors: Jolie Anne BASTIAN, Jiehao CHEN, Jeffrey Daniel COHEN, James Robert HENRY, William Thomas MCMILLEN, Bradley Earl REAMAN, Almudena RUBIO, Daniel Jon SALL, Gaiying ZHAO
  • Aurora A kinase inhibitor
    Patent number: 10010540
    Abstract: The present invention provides an aminopyridine compound, or a pharmaceutically acceptable salt thereof, that inhibits Aurora A and, therefore may be useful in treating cancer.
    Type: Grant
    Filed: January 17, 2017
    Date of Patent: July 3, 2018
    Assignee: Eli Lilly and Company
    Inventor: James Robert Henry
  • 2,3-dihydro-1H-indole compounds
    Patent number: 9872853
    Abstract: The present invention relates to certain novel 2,3-dihydro-1H-indole compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat cancer, more particularly for the treatment of cancer selected from the group consisting of melanoma, acute myeloid leukemia, chronic lymphocytic leukemia, colorectal cancer, breast cancer, lung cancer, ovarian cancer, fallopian tube carcinoma, primary peritoneal carcinoma, cervical cancer, gastric cancer, liver cancer, pancreatic cancer, thyroid cancer, glioma, non-Hodgkin's lymphoma, and Hodgkin's lymphoma.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: January 23, 2018
    Assignee: Eli Lilly and Company
    Inventors: Jolie Anne Bastian, Jiehao Chen, Jeffrey Daniel Cohen, James Robert Henry, William Thomas McMillen, Bradley Earl Reaman, Almudena Rubio, Daniel Jon Sall, Gaiying Zhao
  • 2,3-DIHYDRO-1H-INDOLE COMPOUNDS
    Publication number: 20170354641
    Abstract: The present invention relates to certain novel 2,3-dihydro-1H-indole compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat cancer, more particularly for the treatment of cancer selected from the group consisting of melanoma, acute myeloid leukemia, chronic lymphocytic leukemia, colorectal cancer, breast cancer, lung cancer, ovarian cancer, fallopian tube carcinoma, primary peritoneal carcinoma, cervical cancer, gastric cancer, liver cancer, pancreatic cancer, thyroid cancer, glioma, non-Hodgkin's lymphoma, and Hodgkin's lymphoma.
    Type: Application
    Filed: May 31, 2017
    Publication date: December 14, 2017
    Inventors: Jolie Anne Bastian, Jiehao Chen, Jeffrey Daniel Cohen, James Robert Henry, William Thomas McMillen, Bradley Earl Reaman, Almudena Rubio, Daniel Jon Sall, Gaiying Zhao
  • AURORA A KINASE INHIBITOR
    Publication number: 20170119751
    Abstract: The present invention provides an aminopyridine compound, or a pharmaceutically acceptable salt thereof, that inhibits Aurora A and, therefore may be useful in treating cancer.
    Type: Application
    Filed: January 17, 2017
    Publication date: May 4, 2017
    Inventor: James Robert Henry
  • Aurora A kinase inhibitor
    Patent number: 9637474
    Abstract: The present invention provides an aminopyridine compound, or a pharmaceutically acceptable salt thereof, that inhibits Aurora A and, therefore may be useful in treating cancer.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: May 2, 2017
    Assignee: Eli Lilly and Company
    Inventor: James Robert Henry
  • Aurora A Kinase Inhibitor
    Publication number: 20160137628
    Abstract: The present invention provides an aminopyridine compound, or a pharmaceutically acceptable salt thereof, that inhibits Aurora A and, therefore may be useful in treating cancer.
    Type: Application
    Filed: November 6, 2015
    Publication date: May 19, 2016
    Inventor: James Robert Henry
  • Triazolyl aminopyrimidine compounds
    Patent number: 8114872
    Abstract: The present invention provides triazolyl aminopyrimidine compounds useful in the treatment of cancer.
    Type: Grant
    Filed: May 7, 2008
    Date of Patent: February 14, 2012
    Assignee: Eli Lilly and Company
    Inventors: Joyce Z. Crich, Delu Jiang, Hong-Yu Li, William Thomas McMillen, Jason Scott Sawyer, Melissa Kate Slater, Yan Wang, James Robert Henry, Hong Hu, Sachin Govindlal Maniar
  • Imidazolidinonyl aminopyrimidine compounds for the treatment of cancer
    Patent number: 8101628
    Abstract: The present invention provides novel imidazolidinonyl aminopyrimidine compounds believed to have clinical use for treatment of cancer through inhibiting Plk1. wherein: R1 hydrogen, hydroxy, halo, methyl, C1-C2 alkoxy, amino, or methylamino; R2 is hydrogen, halo, or cyano; R3 is hydrogen or halo; R4 is hydrogen, halo, or methyl; provided that at least two of R1, R2, R3, and R4 are hydrogen; R5 is hydrogen, halo, or methyl; or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: December 11, 2007
    Date of Patent: January 24, 2012
    Assignee: Eli Lilly and Company
    Inventors: Harold Burns Brooks, Joyce Z. Crich, James Robert Henry, Hong-Yu Li, Melissa Kate Slater, Yan Wang
  • PURINE DERIVATIVES AS KINASE INHIBITORS
    Publication number: 20110294792
    Abstract: The present invention provides kinase inhibitors of Formula I.
    Type: Application
    Filed: August 9, 2011
    Publication date: December 1, 2011
    Applicant: ELI LILLY AND COMPANY
    Inventors: Thomas Albert Engler, Timothy Paul Burkholder, Joshua Ryan Clayton, Clive Gideon Diefenbacher, Kelly Wayne Furness, James Robert Henry, Yihong Li, Sushant Malhotra, Angela Lynn Marquart, Johnathan Alexander McLean, David Mendel, Jon Kevin Reel, Brian Raymond Berridge, Charles Edward Ruegg, John Morris Sullivan
  • Imidazolidinonyl aminopyrimidine compounds for the treatment of cancer
    Patent number: 8063212
    Abstract: The present invention provides novel imidazolidinonyl aminopyrimidine compounds believed to have clinical use for treatment of cancer through inhibiting Plk1. Formula I wherein: R1 is aminomethyl, (C1-C3 alkyl)aminomethyl, di(C1-C2 alkyl)aminomethyl, N-ethyl-N-methyl-aminomethyl, 1-aminoethyl, 1-((C1-C2 alkyl)amino)-ethyl, 3,3,3-trifluoro-propylaminomethyl, ethynyl, 2-hydroxy-ethoxy, 2-hydroxyethylaminomethyl, 2-cyanoethylaminomethyl, morpholin-4-ylmethyl, methoxymethoxymethyl, cyclopropyl, 1-azetidinylmethyl, 1-pyrrolidinylmethyl, or 1,3-dioxolan-2-yl; R2 is hydrogen or halo; R3 is hydrogen or halo; provided that at least one of R2 and R3 is hydrogen; R4 is hydrogen, methyl, or halo; and is a single bond that is either present or absent, or pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: December 11, 2007
    Date of Patent: November 22, 2011
    Assignee: Eli Lilly and Company
    Inventors: Harold Burns Brooks, Joyce Z. Crich, James Robert Henry, Hong-Yu Li, Jason Scott Sawyer, Yan Wang
  • Triazolyl aminopyrimidine compounds
    Patent number: 8063035
    Abstract: The present invention provides triazolyl aminopyrimidine compounds useful in the treatment of cancer.
    Type: Grant
    Filed: May 7, 2008
    Date of Patent: November 22, 2011
    Assignee: Eli Lilly and Company
    Inventors: Joyce Z. Crich, James Robert Henry, Hong Hu, Delu Jiang, Hong-Yu Li, William Thomas McMillen, Jason Scott Sawyer, Melissa Kate Slater, Yan Wang
  • Purine derivatives as kinase inhibitors
    Patent number: 8058425
    Abstract: The present invention provides kinase inhibitors of Formula I.
    Type: Grant
    Filed: May 4, 2011
    Date of Patent: November 15, 2011
    Assignee: Eli Lilly and Company
    Inventors: Thomas Albert Engler, Timothy Paul Burkholder, Joshua Ryan Clayton, Clive Gideon Diefenbacher, Kelly Wayne Furness, James Robert Henry, Yihong Li, Sushant Malhotra, Angela Lynn Marquart, Johnathan Alexander McLean, David Mendel, Jon Kevin Reel, Brian Raymond Berridge, Charles Edward Ruegg, John Morris Sullivan
  • Purine derivatives as kinase inhibitors
    Patent number: 8022065
    Abstract: The present invention provides kinase inhibitors of Formula I.
    Type: Grant
    Filed: December 12, 2008
    Date of Patent: September 20, 2011
    Assignee: Eli Lilly and Company
    Inventors: Thomas Albert Engler, James Robert Henry, Sushant Malhotra, Jon Kevin Reel